Eliquis: new oral anticoagulant

Eliquis (apixaban), an oral factor Xa inhibitor, has been launched for the prevention of venous thromboembolism following hip or knee replacement surgery.

Eliquis does not require blood monitoring or adjustment of dose during treatment
Eliquis does not require blood monitoring or adjustment of dose during treatment
PHARMACOLOGY

Apixaban is a reversible, direct, selective inhibitor of factor Xa. It inhibits free and clot-bound factor Xa and prothrombinase, preventing thrombin formation and clot development. Patients receiving apixaban do not require anticoagulation monitoring during treatment.1

CLINICAL STUDIES

Two pivotal, phase 3, double-blind studies compared the thromboprophylactic efficacy of apixaban against the low molecular weight heparin, enoxaparin, following major joint replacement: the ADVANCE-2 study recruited 3057 patients undergoing knee replacement and the ADVANCE-3 study investigated 5407 patients requiring hip replacement.2,3

In both studies, patients were randomised to receive either oral apixaban 2.5mg twice daily starting 12–24 hours after surgery or subcutaneous enoxaparin 40mg once daily starting 12 hours before surgery. Both drugs were continued for 10–14 days following knee surgery or 35 days following hip replacement. The primary endpoint used was a composite of total venous thromboembolic events and all-cause mortality.2,3

Apixaban displayed superior efficacy to enoxaparin in reducing incidence of the primary endpoint in the ADVANCE-2 study (15% vs 24%; relative risk 0.62, 95% CI 0.51-0.74; p<0.0001) and in the ADVANCE-3 study (1.39% vs 3.86%; relative risk 0.36, 95% CI 0.22-0.54; p<0.0001).2,3

Rates of clinically relevant non-major haemorrhage were comparable between the apixaban and enoxaparin groups in both studies. The side-effects most frequently observed with apixaban use are bleeding, anaemia, contusion and nausea.1


References    
1.    Eliquis Summary of Product Characteristics, 2011.
2.    Lassen MR et al. Lancet 2010; 375: 807-15.
3.    Lassen MR et al. N Engl J Med 2010; 363: 2487–98.

View Eliquis drug record

Further information: BMS

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more